Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$24.46 USD
-0.40 (-1.61%)
Updated May 10, 2024 04:00 PM ET
After-Market: $24.50 +0.04 (0.16%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Intellia Therapeutics, Inc. [NTLA]
Reports for Purchase
Showing records 141 - 160 ( 277 total )
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia Receives Authorization to Begin Phase 1/2 trial of NTLA-2002 for Treatment of Hereditary Angioedema (HAE)
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TCR Trial Posted on clinicaltrials.gov for AML
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia Announces IND Acceptance For NTLA-5001, Its First CRISPR/Cas9 Engineered TCR T-Cell Therapy Candidate
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways from Fireside Chat with Genome Editing Powerhouse Intellia; Poised to Round off Catalyst Rich Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Therapeutic Genome Editing Trailblazer Intellia Reports 2Q21 Earnings and Glad Tidings
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Expecting a Full Knockout of TTR in the Next Round
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q21: More Data On Lead Program This Year. Target to $180
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NOVO Nordisk Acquires Prothena TTR Amyloidosis Candidate; Reinforces Confidence in Large TTR Amyloidosis Market.
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Platform-Validating Interim Data Readout Reinforces Our Enthusiasm for the Stock
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
An Impressive Start for NTLA-2001: Model Adjustment
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D